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Abstract
Cardiac myosin binding protein-C (cMyBP-C) is a multi-domain (C0–C10) protein that regulates heart muscle contraction
through interaction with myosin, actin and other sarcomeric proteins. Several mutations of this protein cause familial
hypertrophic cardiomyopathy (HCM). Domain C1 of cMyBP-C plays a central role in protein interactions with actin and
myosin. Here, we studied structure-function relationship of three disease causing mutations, Arg177His, Ala216Thr and
Glu258Lys of the domain C1 using computational biology techniques with its available X-ray crystal structure. The results
suggest that each mutation could affect structural properties of the domain C1, and hence it’s structural integrity through
modifying intra-molecular arrangements in a distinct mode. The mutations also change surface charge distributions, which
could impact the binding of C1 with other sarcomeric proteins thereby affecting contractile function. These structural
consequences of the C1 mutants could be valuable to understand the molecular mechanisms for the disease.
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Introduction
Hypertrophic cardiomyopathy (HCM) is an inherited heart
disease that has continued to interest and intrigue clinicians,
molecular biologists, biochemists and modellers [1–4]. HCM is
usually caused by mutations in the genes encoding for sarcomeric
proteins [5–8]. To date, more than 800 mutations have been
reported in the genes that encode for sarcomeric proteins [9,10].
However, the mechanism by which a gene mutation can cause
such a massive difference in the phenotype and its function
remains largely unknown. Therefore, the objective of this study is
to investigate the basic mechanism by which the mutations
translate to the phenotype.
The sarcomere is the basic unit of a muscle and it is composed
of a variety of proteins including myosin and actin as the major
components that form thick and thin filaments, respectively. Other
accessory proteins such as myosin binding protein-c (MyBP-C)
[11], titin, troponin, tropomyosin etc. take part in maintaining
structure and regulating function of the sarcomere.
A mutational analysis study on an Egyptian cohort through
Bibliotheca Alexandrina HCM (BA-HCM), a national programme
showed that mutations in cardiac MyBP-C (cMyBP-C) gene are
a common cause of HCM in Egypt [12]. More than 200 disease
causing mutations have been reported in the cMyBP-C [7,13–19].
cMyBP-C is a large sarcomeric protein with multiple domains
and a component of thick filaments [20–22]. It is solely expressed
in the heart of mammals [23,24]. The structure of cMyBP-C is
composed of 11 domains including eight immunoglobuline(Ig)-like
domains and three fibronectin(Fn)-like domains, which are termed
as C0–C10 [25]. Each domain is a globular protein. The three-
dimensional structure is available for only a few of the domains
including C0, C1, C2 and C5 [26–30]. The N-terminus of the
protein including domains C0, C1, cMyBP-C motif and C2 plays
a significant role in the regulation of interaction with myosin
[31,32] and/or actin [33,34]. Specifically, the domain C1 has
been found to interact with sub-fragment 2 of myosin [26]. In
addition, N-terminal of this domain might bind with actin through
Pro-Ala rich region [27].
Here, we studied three disease causing missense mutations of
the domain C1 that were recently identified in Egypt for the first
time by Kassem et al., [12]. These HCM causing mutations: (i)
Arg177His (ii) Ala216Thr and (iii) Glu258Lys are located in the
strand-B, the D/E loop and the C-terminal of strand-G,
respectively (Figure 1). These mutations have also been reported
by others in different parts of the world [35–37]. In particular,
Glu258Lys has been reported to cause a founder effect in Italian
population [38]. Clinical studies suggest the effect of mutations (ie.,
contractile dysfunction [7,8,12,15,18,36–38]), yet less is known
about their structure-function relationship. Although the structural
positions of the mutations are known [26–28], their exact role in
causing HCM is unclear. Computational biology might prove as
a valuable tool at the molecular level. These include molecular
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dynamics (MD) simulations, Floppy Inclusions and Rigid Sub-
structure Topography (FIRST) [39], and electrostatic potential
calculations. Here, we have used these techniques to analyse the
mutation-induced changes in the structural and electrostatic
properties that could alter the function of the C1 and cMyBP-C,
and might therefore lead to the disease.
Materials and Methods
Model Repair
The high resolution crystal structure of domain C1 of cMyBP-C
(PDB ID: 2V6H, 1.55 A˚) [27] was taken from the protein data
bank (PDB, http://www.rcsb.org/pdb/) for our study. The C1
consists of seven b-stands that form two b-sheets, where sheet-1
consists of strands A, C, F and G while sheet-2 comprises strands
B, D and E, both with anti-parallel packing of adjacent strands
(Figure 1). The structure of domain C1 has four missing residues
(Ala181-Leu184) in the B/C loop. The Discovery Studio V3.1
(DS) was used to construct the missing residues (Accelrys, San
Diego, USA) [40] and the resulting model was subjected to energy
minimization using Groningen Machine for Chemical Simulation
(GROMACS) V4.5.4. The energy minimized C1 structure was
used to build the mutants that were modelled using the DS ‘‘build
and edit protein’’. A total of four MD simulations were carried out
including one wild type and three mutant C1 structures with
production runs of 10 ns.
MD Simulations of Domain C1 of cMyBP-C
Energy minimization was carried out for the domain C1 using
the steepest descent algorithm with a tolerance of 2000 kJ/mol/
nm using the GROMACS simulation package [41,42]. The
energy minimized structure was used as the starting structure for
the MD simulations. The GROMOS96 [43] force field was
applied to the C1 structure while the SPC3 [44] water model was
used to create the aqueous environment. The protein was solvated
in a cubic box with the size of 0.8 nm. Periodic boundary
conditions were applied in all directions and the system was
neutralized by adding Na+ ions. The resulting systems contain
,30860 atoms. A twin range cut-off was used for long-range
interactions: 0.8 nm for van der Waals interactions and 1.4 nm for
electrostatic interactions. All bond lengths were constrained with
the LINCS [45] algorithm. The SETTLE [46] algorithm was
applied to constrain the geometry of the water molecules. The
energy minimized system was subjected to 100 ps equilibration.
This pre-equilibrated system was subsequently subjected to 10 ns
of production MD simulations with a time-step of 2 fs at constant
temperature (300 K), pressure (1 atm) and number of particles,
without any position restraints [47]. The snapshots were collected
at every 10 ps. The trajectories were analyzed using GROMACS
analysis tools and the structures were analyzed using DS and
PyMOL (www.pymol.org).
Rigidity Analysis
The program FIRST is used to identify rigid and flexible
regions of the C1 network graphs. In FIRST, the cut-off
parameters for the energy and the hydrophobic interactions were
set to 20.7 and 1.0, respectively. Structural degrees of freedom,
intra-molecular interactions and number of rigid clusters were also
calculated.
Electrostatic Surface Calculation
The electrostatic potential was calculated for the WT as well as
the mutants using the Delphi package provided in the DS. The
Delphi charges were assigned for the structures and the surface
electrostatic potential map was obtained by solving the Poisson-
Boltzmann equation.
Results
Trajectory-based Analyses for the MD Simulated Systems
In order to find out the structural stability of WT and
mutants of the C1 dynamically, root mean square deviation
(RMSD) was computed with respect to their initial structures for
the Ca-atoms (Figure 2A) throughout the MD simulations. It
showed that the deviation pattern was different for WT and
mutants. However, after the equilibration phase, all the systems
stayed within ,0.3 nm and this suggested that the structures
remain stable.
To determine the flexible regions of the systems, the average
root mean square fluctuations (RMSF) were calculated for 10 ns of
the MD simulations and generated as a 2D plot with respect to the
Ca-atoms of the residues (Figure 2B). Here, residues that are
fluctuated more than 0.2 nm considered as flexible regions. As
expected, the long loop at the N-terminal and the loops B/C, C/D
and F/G were observed as flexible regions while the rest of the
domain remained rigid.
These trajectory-based analyses have not provided significant
differences in the behaviour of the systems. Hence, we tried to
examine the individual structures in detail to see whether the
mutations induced any changes in the secondary structural
elements during the simulations. For this purpose, every one
nanosecond structures were collected, observed and analysed for
10 ns.
Figure 1. Structural features of the domain C1 of cMyBP-C.
Positions of the examined HCM causing mutations are shown in red.
The C1 consists of seven b-stands that form two b-sheets, where sheet-
1 consists of strands A, C, F and G while sheet-2 comprises strands B, D
and E both with anti-parallel packing of adjacent strands. Refer Figure 4
and 6 for the key residues.
doi:10.1371/journal.pone.0059206.g001
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Secondary Structural Changes and Interactions of the
Mutated Residues
The nature of the secondary structural elements in the WT
(core structure) has been conserved during the MD simulations
(Figure 3Aa, 3Ba and 3Ca). However, all three mutants displayed
changes in their secondary structural elements at several stages of
the MD simulations and the structures that showed major changes
are represented in Figure 3Ab, 3Bb and 3Cb. Lose of secondary
structural changes in the strand A (Fig. 3Bb and 3Cb) was not
considered in the analysis, as it might be due to the highly flexible
long N-terminal loop (Fig. 2B).
Here, we studied interactions of the residues at positions 177/
216/258 with their neighbouring residues in the WT and mutants
in order to investigate whether behaviour of the mutants might be
the cause for the observed structural changes. This has been
performed by identifying two layers of neighbouring residues
which are connected via hydrogen bonds. Here, the residues
which interact directly with the residue at 177/216/258 are called
as first layer residues and the residues that are (indirectly) linked
with 177/216/258 through a mediator that is via the first layer
residues are considered as the second layer of residues.
At 10 ns of the Arg177His mutant simulation, a major part of
the b-strand D has been converted into loop that extend the D/E
loop (Figure 3Ab). This structural change occurred in the vicinity
of the strand B, where the relevant mutation is positioned. Here,
we monitored interactions between the residue 177 and its
neighbouring residues. In the WT, Arg177 directly interacts with
Met159, Ser175 and Ser217 and these residues further contact
Asp214 and Val219 (Figure 4Aa). Whereas, in the mutant, His177
forms hydrogen bonds with Val158, Met159, Asp214, Ser217 and
Val219 at the first layer and the network extends further through
Leu156 and Lys218 (Figure 4Ab).
The mapping of intra-molecular interactions associated with the
residue 177 shows that the network based on Arg177 is smaller than
Figure 2. Trajectory-based structural stability analyses of WT and mutants. (A) Root mean square deviation (RMSD) and (B) average root
mean square fluctuation (RMSF) of residues during MD simulations.
doi:10.1371/journal.pone.0059206.g002
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the one based on His177. It is mainly because of the exposed side-
chain of the arginine that was not involved in to form many
interactions in WT, whereas, the ring structure of His177 fits well
within the interaction pocket to make many interactions. The
increase in the number of hydrogen bonds based on His177 at this
region introduce more bonding constrains that could affect its local
flexibility.
At 9 ns of the simulation of the mutant Ala216Thr, the length of
the F helix has been increased and the long strand G has been
divided into two strands, while the mutation spot is located at the
loop D/E (Figure 3Bb). The native residue alanine at 216 makes
no contacts because it is exposed to the surface from the loop D/E
and due to its short side-chain. On the other hand, the long side-
chained hydrophilic residue threonine at 216 forms hydrogen
bonds with Asp214, Ser217 and Lys218 and they continue the
network with Gly180 and Val219 (Figure 4B).
Although the interaction pattern has been altered near the loop
D/E, the structural change has occurred at the F-G interface. It
suggests that the impact of this mutation could be at the distal
regions of the domain C1 (Figure 3Bb) where some of the
interactions are modified. This behaviour is different from the
previous mutation studied above (Figure 3Ab).
At 1 ns of the mutant Glu258Lys, half of the long strand-G has
been converted into a loop. The mutation spot is located at the C-
terminal region of this strand. The Glu258 in the WT directly
interacts with Val256 of the same strand-G and indirectly with
Phe233 of the loop E/F via Val256, while, Lys258 has no
interactions with its nearby residues (Figure 4C). This mutation
has similar behaviour as the Arg177His, which affects the
neighbouring regions indirectly.
The mapping of neighbouring contacts shows the local
hydrogen bonding networks that are associated with the residues
at the mutational positions. However, for all three mutations, it
indicates that they are not directly involved in triggering the
secondary structural changes. Thus, to relate these changes to the
secondary structural changes, we analysed the fluctuations of the
mutated residues during the MD simulations. The average RMSF
(Figure 5) for 10 ns of the systems shows different behaviour for
the WT and the mutated residues at their corresponding positions.
The arginine at position 177 fluctuates higher than the histidine at
the same position and a similar behaviour was observed for
Glu258Lys, where glutamic acid fluctuates slightly higher than
lysine. On the other hand, the mutated residue thronine fluctuates
significantly more than the native alanine. These results imply that
modifying the long side-chain residues (Arg) to short (His) and vice
versa (Ala, to Thr and Glu to Lys) at key positions could make
them rigid or flexible, respectively. This might induce a local
structural instability and intervene with the native bonding of
neighbouring residues which can induce structural changes.
Figure 3. Secondary structural changes. The representative snapshots of WT and mutants are shown. (A) a) WT and b) Arg177His at 10 ns, (B) a)
WT and b) Ala216Thr at 9 ns and (C) a) WT and b) Glu258Lys at 1 ns. In the structures, red color cartoon and black arrows indicate position of the
mutation.
doi:10.1371/journal.pone.0059206.g003
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Rigidity and Flexibility of Residues Linked with Structural
Changes
The identification of changes in rigid and flexible regions in the
WT and mutated systems of C1 can provide a molecular
explanation for the secondary structural changes at the affected
regions. FIRST is a program that identifies rigidity and flexibility
of substructures in a macromolecule and offers details related to
intra-molecular interactions. Therefore, we used FIRST to analyse
the representative 3D structures to monitor the key hydrogen
bonds, which normally determine the rigidity, and the residues
that are involved in the formation of b-sheets. We focused our
analyses towards the structurally modified regions of the b-sheets
(Figure 6), which could affect the rigidity of the rest of the domain
that are structurally conserved.
The structural architecture of a typical antiparallel b-sheet is
important to maintain integrity of domain C1 and other Ig-like
domains of cMyBP-C [26–30]. These types of sheets are
constructed with antiparallel b-strands and the majority of the
building blocks are hydrophobic residues. The b-sheet is formed
through making hydrogen bonds between carbonyl oxygen of one
Figure 4. Intra-molecular interactions. For the represented snapshots of MD simulations (Figure 3), two layers of neighbouring residues between
corresponding WT and mutant residues along with their hydrogen bonds are displayed. Here, (A) a) WT and b) Arg177His at 10 ns, (B) Ala216Thr at
9 ns and (C) WT at 1 ns. At 9 ns Ala216 of WT and at 1 ns Lys258 of Glu258Lys did not make any interactions, hence they are not shown. WT and
mutant residues 177, 216 and 258 are shown in yellow, and the residues directly interacting with these residues are shown in pink and are described
as first layer. The residues that are interacting with first layer of residues are depicted as second layer and shown in violet.
doi:10.1371/journal.pone.0059206.g004
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strand and amino hydrogen atom of the other strand. Thus, each
residue from the strand-1 makes two hydrogen bonds with their
neighbours on the strand-2. This bonding pattern is required for
the formation of a successful b-sheet. Interfering with any of the
residues in the sheet via an inappropriate mutation will not only
break the continuity of the bonding pattern but also make the side-
chain of the mutated residue flexible, which could disrupt the
natural bonding of neighbours and might result in loss of rigidity
or secondary structural elements.
In the WT and the Arg177His at 10 ns, we focused on the
sheet-2 as it is the structurally modified region due to the mutation.
Here, the sheet is shown into two interfaces, the B-E and D-E
interfaces (Figure 6Aa–b). The secondary structural change in the
B-E interface was observed at the C-terminal of the strand B and
D. At this region, the sheet was maintained with two hydrogen
bonds between Val178 and Tyr220 in the WT. However, one of
the hydrogen bonds between these two residues was lost in the
mutant which resulted in the side-chain movement of Tyr220.
This side-chain movement of Tyr220 now forms another
hydrogen bond with Gly180, which is also flexible as it is in the
B/C loop. The movement of the aromatic side-chain of Tyr220
appears to affect the bonding pattern in its vicinity especially at the
D-E interface of Arg177His. Although the Ser212 forms two
hydrogen bonds with Leu221 in both WT and Arg177His, in the
latter case one of the hydrogen bonds is not from the backbone
atom. This change together with the motion of Tyr220 might
affect the remaining b-strand D and cause rearrangement in the
pattern of hydrogen bonds such as loss of hydrogen bonds between
Ser217 « Val219 and Arg215 « Lys218 and formation of new
hydrogen bonds between Asp214 « Ser217 and Asp214 «
Val219 (Figure 6Ab) (« indicates a single hydrogen bond). These
changes might have caused the loss of secondary structure in the
D–E interface.
These results suggest that replacement of Arg177 to histidine
initiates the changes by disturbing the normal bonding of
neighbour Val178 with Tyr220. This tyrosine becomes flexible
and interrupts the usual bonding of its neighbour Leu221 with
Ser212 and rearranges the pattern of hydrogen bonds of the other
mentioned pairs and thus could bring structural change at strand
B, D and E.
The next mutation (Ala216Thr) is located on the loop D/E in
the sheet-2, which affected the distal region at the F–G interface in
the sheet-1. In this case, Arg238 of WT formed a strong charge
based interaction with Glu240, which was missing in the mutant
Ala216Thr and Gly194 formed a new interaction with Ser236 at
the C-F interface (Figure 6Ba–b). While in the F–G interface,
Gly235 of WT formed two hydrogen bonds with Leu254.
However, the backbone interactions were lacking in the mutant
between Gly235 and Leu254 rather they gained one of their lost
interactions through contacting Thr255 and Phe252, respectively.
This rearrangement of hydrogen bonds induced breakage of the
strand G in Ala216Thr, this change brought the E/F loop closer
and helped in the establishment of new hydrogen bonds between
Phe233 « Gln230. Moreover, this type of change played a role in
rearrangement of hydrogen bonds at the F/G loop region (data
not shown) such as loss of three hydrogen bonds between Phe247
« Lys246 and Lys246 u Asp248 and formation of hydrogen
bonds between Thr243 u Lys246 and Lys246 « Asp245
(Figure 6Bb, u two hydrogen bonds).
The observed changes in this mutation occurred at the mid of
the F–G interface. Although this region is away from the
mutational spot on the D/E loop, these two regions are linked
by the strand E and the E/F loop. The changes are possibly
initiated by the Gly235 (and Thr234), which affected its normal
interactions with Leu254 and thereby modified the usual bonding
pattern of several residues in the vicinity. Thus, it indicates that the
mutation at the other end of the segment in the C1 at some point
could induce the structural changes through the strand E–E/F
loop.
In the Glu258Lys at 1 ns, the sheet-1 has been affected. Here, at
1 ns of WT in the F–G interface, Val256 forms a hydrogen bond
with Phe233 (Figure 6Ca–b). This hydrogen bond is missing in the
mutant. In addition, new hydrogen bonds were observed between
Pro231 « Thr234, Phe233 « Tyr237, Thr234 « Val256. This
rearrangement (loss and gain) in the hydrogen bonding pattern
could have affected the structure locally (the G-strand).
Here, the observed changes suggest that mutating a small
negatively charged residue Glu258 into a long side-chained
positively charged lysine at the C-terminal of the strand G can
initiate the structural changes through its neighbouring region. It
might have started to intervene with the bonding of Val 256 with
Phe233. This was not observed in the mutant. This change has
affected the bonding pattern of its neighbours and modified usual
Figure 5. Fluctuations of the WT and mutant residues during MD simulations. The average RMSF of the mutated residues for 10 ns are
plotted in 2D bar graph. The bars in gray and in different colours (green, orange and aqua green) represent the WT and the mutants, respectively.
doi:10.1371/journal.pone.0059206.g005
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network of several residues nearby and could have transformed the
long strand into two strands divided by a loop.
The rigidity analysis together with RMSF results suggest that
the fluctuations of the three mutated residues can cause indirect
effects on the rigidity of the domain by breaking/making of
interactions with its neighbouring residues thus modifying
secondary structural elements.
Mutational Impact on the Electrostatic Surface of the
Systems
The change in the internal molecular architecture can alter the
surface charge distribution, which is important for protein-protein
interactions. It is significant for this study as C1 in cMyBP-C interacts
with myosin and actin using surface electrostatic properties [26,27].
Here, the results of the electrostatic calculations (Figure 7 WT
and Arg177His at 10 ns) showed that His177 with the help of
Leu156, Val158 and Met159 pushes Arg160 near the mutated
region to introduce a positive patch in between the negative
surface. On the other side, the changes at the sheet-2 bring down
Lys185 and Lys190 through the B/C loop to create space for
a negative surface created by Glu240 and Asp198.
The Thr216 interaction with Asp214 allows Arg160 and
Arg177 to project a positive surface near the strand B.
Furthermore, the change in the distal region at the N-terminal
loop affects the neighbour loop F/G and brings the hydrophobic
surface through Phe247 (Figure 7, WT and Ala216Thr at 9 ns).
The position of 258, which is highly conserved with negatively
charged glutamic acid in cMyBP-C for most of the organisms, was
replaced with a positively charged lysine residue in the mutant
Glu258Lys. Hence, the presence of Lys258 is responsible for the
formation of a positive patch at the C-terminal in this mutant at both
the front and back view of the 1 ns snapshots (Figure 7 WT and
Glu258Lys).
The structural basis of the interactions in the domain C1
depends on conformational integrity and surface charge distribu-
tions. Here, results from our study reveal how the mutations in
a single domain can initiate structural changes by altering the
intra-molecular interactions. These internal changes could bring
local structural constrains and affect the formation of secondary
structural elements. Consequently, it influences the domain
conformation and modifies the nature of surface charge distribu-
tion, which is important for this domain to interact with
neighbouring domains and to interact with other sarcomeric
proteins such as myosin and actin to regulate muscle contraction.
Figure 6. Molecular explanations for the structural changes. The rigidity analysis provided information based on the structural rigidity and
flexibility of residues. (A) 10 ns snapshots of a) WT and b) Arg177His, (B) 9 ns snapshots of a) WT and b) Ala216Thr and (C) 1 ns snapshots of a) WT
and b) Glu258Lys. Here, blue represents rigid regions and black and gray indicates flexible regions. The mutational spots are shown in yellow arrow.
As the Ala216Thr affected the distal region of the domain, the position of this mutation has not shown. The hydrogen bonds (red lines) that are
missing in the mutants are marked in black and the newly formed hydrogen bonds in the mutants are shown in light blue.
doi:10.1371/journal.pone.0059206.g006
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Discussion
This study has shown that the disease causing mutations affect
the structural properties of domain C1 through changing (i)
residue flexibility/rigidity (ii) intra-molecular interactions, (iii)
secondary structural elements and (iv) surface electrostatics. As
these changes are inter-linked, this chain of modifications might
leads to altered molecular mechanism. Arg177His and Glu258Lys
have similar patterns such as via affecting its neighbouring regions,
sheet-2 and sheet-1, respectively. In contrast, Ala216Thr affects
the distal region from the mutational spot of the C1.
The domain C1 is flanked by a structurally and functionally
important proline-alanine rich region and the cMyBP-C motif on
both sides. The proline-alanine rich region regulates cross-bridge
speed thus plays a significant role in the sarcomere [48]. Whereas, the
conserved motif is found to be interacting with sub-fragment 2 of
myosin [26]. Hence, any structural change in the domain C1 might
reflect in the function.
The relationship between structural change and molecular
mechanism is fundamental in understanding phenotype [49]. The
structural changes observed here in domain C1 could disturb
phosphorylation sites on neighbouring motif and thereby influence
Ca2+ signalling and energy supply for contractile function, thus
producing energy depletion which has been identified as possible
mechanism in HCM [8,50]. Recent reports support the notion
that the normal phosphorylation in the motif regulates the Ca2+-
dependent interactions between cMyBP-C [51] and calmodulin
(CaM)/calmodulin kinase II (CaMKII, [52]) and thus dysregula-
tion of calcium handling could be produced by the structural
changes reported here, thereby play an important role in the
pathophysiology of HCM. Furthermore, the changes in electro-
static and structural properties due to the mutations in C1 could
impact neighbouring phosphorylation sites. This is supported by
the fact that the removal of cMyBP-C from native cardiac thick
filaments slowed down motion generation of actomyosin, which
was also modulated by phosphorylation [53]. However, it is
unclear that how these types of disease causing mutations are not
blocked by the natural quality control systems (mRNA decay,
ubiquitin-proteasome system and autophagy), which commonly
control their expressions [54]. This opens up new research avenues
to explore molecular therapeutic agents that can reinforce the
natural way of quality control to prevent this cardiac disease.
In conclusion, the HCM causing mutations studied here poten-
tially changes the native structural properties of the domain C1 of
cMyBP-C. We have given possible molecular explanations to
understand how the mutations could initiate the malfunction. It has
shown that three mutations have different mechanisms to disturb the
structural integrity of the domain C1. The molecular changes
described here could distract binding of the molecule to actin and/or
myosin and thus interfere with both contractile and electrical
functions. As cMyBP-C is a major player in functional regulation
and structural integrity of the sarcomere, its dysregulation can be
responsible for at least some of the pathological changes observed in
HCM.
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